3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
32
Pain, Postoperative
18
Neoplasms
15
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Lung Neoplasms
12
Brain Neoplasms
12
Prostatic Neoplasms
9
Ovarian Neoplasms
8
Colonic Neoplasms
8
Carcinoma, Hepatocellular
8
Stomach Neoplasms
7
Depression
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Pain
6
Head and Neck Neoplasms
6
Thyroid Neoplasms
5
Pancreatic Neoplasms
5
Multiple Myeloma
5
Leiomyoma
5
Agnosia
5
Neoplasm Metastasis
4
Lymphoma
4
Fatigue
4
Delirium
4
Anxiety Disorders
4
Urinary Bladder Neoplasms
3
Thromboembolism
3
Supratentorial Neoplasms
3
Stomatitis
3
Interventions
Paclitaxel
24
Hyperthermic Intraperitoneal Chemotherapy
24
Cisplatin
22
Oxaliplatin
17
Carboplatin
17
Fluorouracil
13
Cytoreduction Surgical Procedures
13
Bevacizumab
10
Mitomycin
9
Leucovorin
8
Doxorubicin
8
Docetaxel
6
Gemcitabine
5
130-nm albumin-bound paclitaxel
5
Surgical Procedures, Operative
4
Blood Specimen Collection
4
Albumin-Bound Paclitaxel
4
sodium thiosulfate
3
liposomal doxorubicin
3
catumaxomab
3
Taxes
3
Neoadjuvant Therapy
3
Laparoscopy
3
Drug Therapy
3
tremelimumab
2
relacorilant
2
pembrolizumab
2
olaparib
2
nintedanib
2
epothilone B
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Peritoneal Neoplasms
×
Saline Solution
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts